NO317350B1 - Peptid p277 analoger og farmasoytiske sammensetninger som omfatter disse for behandling eller diagnostikk av diabetes - Google Patents

Peptid p277 analoger og farmasoytiske sammensetninger som omfatter disse for behandling eller diagnostikk av diabetes Download PDF

Info

Publication number: NO317350B1
Authority: NO; Norway
Prior art keywords: peptide; cells; cell; hsp60; iddm
Prior art date: 1994-12-21

Application number

NO19972849A

Other languages

English (en)

Norwegian (no)

Other versions

NO972849L (no

NO972849D0 (no

Inventor

Dana Elias

Irun R Cohen

Matityahu Fridkin

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-21

Filing date

1997-06-19

Publication date

2004-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26322965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO317350(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-12-21 Priority claimed from IL11209494A external-priority patent/IL112094A0/xx

1995-07-05 Priority claimed from IL11446095A external-priority patent/IL114460A0/xx

1997-06-19 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

1997-06-19 Publication of NO972849D0 publication Critical patent/NO972849D0/no

1997-08-13 Publication of NO972849L publication Critical patent/NO972849L/no

2004-10-18 Publication of NO317350B1 publication Critical patent/NO317350B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 127
238000011282 treatment Methods 0.000 title claims description 47
239000008194 pharmaceutical composition Substances 0.000 title claims description 11
238000003745 diagnosis Methods 0.000 title claims description 6
206010012601 diabetes mellitus Diseases 0.000 title description 53
210000001744 T-lymphocyte Anatomy 0.000 claims description 84
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 65
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 50
108010058432 Chaperonin 60 Proteins 0.000 claims description 42
102000006303 Chaperonin 60 Human genes 0.000 claims description 42
239000000427 antigen Substances 0.000 claims description 33
102000036639 antigens Human genes 0.000 claims description 33
108091007433 antigens Proteins 0.000 claims description 33
238000000034 method Methods 0.000 claims description 29
102000004196 processed proteins & peptides Human genes 0.000 claims description 25
238000012360 testing method Methods 0.000 claims description 24
210000004369 blood Anatomy 0.000 claims description 21
239000008280 blood Substances 0.000 claims description 21
210000004027 cell Anatomy 0.000 claims description 16
238000002360 preparation method Methods 0.000 claims description 13
108090000695 Cytokines Proteins 0.000 claims description 10
102000004127 Cytokines Human genes 0.000 claims description 10
239000002773 nucleotide Substances 0.000 claims description 10
125000003729 nucleotide group Chemical group 0.000 claims description 10
230000006052 T cell proliferation Effects 0.000 claims description 9
210000004698 lymphocyte Anatomy 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 8
230000004044 response Effects 0.000 claims description 7
150000003839 salts Chemical group 0.000 claims description 7
239000003431 cross linking reagent Substances 0.000 claims description 6
238000010348 incorporation Methods 0.000 claims description 6
238000011534 incubation Methods 0.000 claims description 6
210000005087 mononuclear cell Anatomy 0.000 claims description 6
230000002062 proliferating effect Effects 0.000 claims description 5
210000002700 urine Anatomy 0.000 claims description 5
102100037850 Interferon gamma Human genes 0.000 claims description 4
108010074328 Interferon-gamma Proteins 0.000 claims description 4
102000003814 Interleukin-10 Human genes 0.000 claims description 4
108090000174 Interleukin-10 Proteins 0.000 claims description 4
108090000978 Interleukin-4 Proteins 0.000 claims description 4
230000002238 attenuated effect Effects 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
238000000338 in vitro Methods 0.000 claims description 4
108010002350 Interleukin-2 Proteins 0.000 claims description 3
108090001005 Interleukin-6 Proteins 0.000 claims description 3
238000003149 assay kit Methods 0.000 claims description 3
238000010382 chemical cross-linking Methods 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 3
230000003436 cytoskeletal effect Effects 0.000 claims description 3
230000002706 hydrostatic effect Effects 0.000 claims description 3
238000002965 ELISA Methods 0.000 claims description 2
101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 claims description 2
102000000588 Interleukin-2 Human genes 0.000 claims description 2
102000004388 Interleukin-4 Human genes 0.000 claims description 2
102000004889 Interleukin-6 Human genes 0.000 claims description 2
102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 claims description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
238000004113 cell culture Methods 0.000 claims description 2
238000003127 radioimmunoassay Methods 0.000 claims description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
241000699670 Mus sp. Species 0.000 description 77
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 24
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 16
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 14
239000008103 glucose Substances 0.000 description 14
229960001052 streptozocin Drugs 0.000 description 14
230000001363 autoimmune Effects 0.000 description 13
239000000839 emulsion Substances 0.000 description 10
239000003921 oil Substances 0.000 description 10
235000019198 oils Nutrition 0.000 description 10
230000008569 process Effects 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
102000004877 Insulin Human genes 0.000 description 8
108090001061 Insulin Proteins 0.000 description 8
229940125396 insulin Drugs 0.000 description 8
229940028435 intralipid Drugs 0.000 description 8
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
201000001421 hyperglycemia Diseases 0.000 description 7
239000002480 mineral oil Substances 0.000 description 7
235000010446 mineral oil Nutrition 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
230000002269 spontaneous effect Effects 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
239000012634 fragment Substances 0.000 description 6
230000009696 proliferative response Effects 0.000 description 6
210000000952 spleen Anatomy 0.000 description 6
OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 5
239000002671 adjuvant Substances 0.000 description 5
230000005784 autoimmunity Effects 0.000 description 5
108010004073 cysteinylcysteine Proteins 0.000 description 5
230000006378 damage Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
230000001904 diabetogenic effect Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
229940104230 thymidine Drugs 0.000 description 5
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
241000611421 Elia Species 0.000 description 4
206010018429 Glucose tolerance impaired Diseases 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
230000005867 T cell response Effects 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
238000003556 assay Methods 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000002960 lipid emulsion Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
102000008214 Glutamate decarboxylase Human genes 0.000 description 3
108091022930 Glutamate decarboxylase Proteins 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000001516 cell proliferation assay Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000010998 test method Methods 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000002812 Heat-Shock Proteins Human genes 0.000 description 2
108010004889 Heat-Shock Proteins Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
230000003345 hyperglycaemic effect Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000004153 islets of langerhan Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
230000035764 nutrition Effects 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
235000012424 soybean oil Nutrition 0.000 description 2
239000003549 soybean oil Substances 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101100327692 Caenorhabditis elegans hsp-60 gene Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
108010067035 Pancrelipase Proteins 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
206010040914 Skin reaction Diseases 0.000 description 1
NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
238000009171 T-cell vaccination Methods 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
210000001728 clone cell Anatomy 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000010432 diamond Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
239000008344 egg yolk phospholipid Substances 0.000 description 1
229940068998 egg yolk phospholipid Drugs 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
101150086609 groEL2 gene Proteins 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical group [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
235000020925 non fasting Nutrition 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000007425 progressive decline Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
229940021993 prophylactic vaccine Drugs 0.000 description 1
238000012797 qualification Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000035483 skin reaction Effects 0.000 description 1
231100000430 skin reaction Toxicity 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Diabetes (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Veterinary Medicine (AREA)
Rehabilitation Therapy (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

NO19972849A 1994-12-21 1997-06-19 Peptid p277 analoger og farmasoytiske sammensetninger som omfatter disse for behandling eller diagnostikk av diabetes NO317350B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IL11209494A IL112094A0 (en)	1994-12-21	1994-12-21	Novel peptides and pharmaceutical compositions comprising them
IL11446095A IL114460A0 (en)	1995-07-05	1995-07-05	Peptide p277 analogs and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
PCT/US1995/016596 WO1996019236A1 (en)	1994-12-21	1995-12-20	PEPTIDE p277 ANALOGS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR TREATMENT OR DIAGNOSIS OF DIABETES

Publications (3)

Publication Number	Publication Date
NO972849D0 NO972849D0 (no)	1997-06-19
NO972849L NO972849L (no)	1997-08-13
NO317350B1 true NO317350B1 (no)	2004-10-18

Family

ID=26322965

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19972849A NO317350B1 (no)	1994-12-21	1997-06-19	Peptid p277 analoger og farmasoytiske sammensetninger som omfatter disse for behandling eller diagnostikk av diabetes

Country Status (31)

Country	Link
EP (1)	EP0820303B1 (de)
JP (2)	JP3420245B2 (de)
KR (1)	KR100400480B1 (de)
CN (1)	CN1233417C (de)
AR (1)	AR002949A1 (de)
AT (1)	ATE242005T1 (de)
AU (1)	AU707835B2 (de)
BR (1)	BR9510102A (de)
CA (1)	CA2208274C (de)
CZ (1)	CZ293784B6 (de)
DE (2)	DE69531004T2 (de)
DK (1)	DK0820303T3 (de)
ES (1)	ES2201137T3 (de)
FI (1)	FI118373B (de)
HR (1)	HRP950612B1 (de)
HU (1)	HU224160B1 (de)
IL (1)	IL116499A0 (de)
IS (1)	IS1966B (de)
MX (1)	MX9704738A (de)
NO (1)	NO317350B1 (de)
NZ (1)	NZ301440A (de)
PL (1)	PL184145B1 (de)
PT (1)	PT820303E (de)
RO (1)	RO116777B1 (de)
RS (1)	RS49517B (de)
SI (1)	SI0820303T1 (de)
TR (1)	TR199501630A2 (de)
TW (1)	TW496872B (de)
UA (1)	UA42040C2 (de)
UY (1)	UY24130A1 (de)
WO (1)	WO1996019236A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6488933B2 (en)	1995-07-05	2002-12-03	Yeda Research And Development Co. Ltd.	Preparations for the treatment of T cell mediated diseases
US6451541B1 (en) *	1996-05-14	2002-09-17	Ernst-Ludwig Winnacker	Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPsc
WO2002016549A2 (en) *	2000-08-25	2002-02-28	Yeda Research And Development Co. Ltd.	METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE
IL140233A0 (en) *	2000-12-11	2002-02-10	Peptor Ltd	Backbone cyclized analogs of heat shock proteins
EP1575479A4 (de)	2002-01-31	2006-10-25	Develogen Israel Ltd	Hsp-peptide und analoga zur modulation von immunantworten über antigen präsentierende zellen
CA2595520A1 (en) *	2004-01-28	2005-08-11	Develogen Israel Ltd.	Hsp therapy in conjunction with a low antigenicity diet
DE102004043750A1 (de) *	2004-09-10	2006-03-30	Sanofi-Aventis Deutschland Gmbh	Formulierungen des Peptids p277 oder dessen Varianten mit optimierter Stabilität
CN100352502C (zh) *	2004-12-29	2007-12-05	中国药科大学	能通过免疫防治ⅰ型糖尿病的重组蛋白和重组基因
EP1835933A4 (de) *	2005-01-04	2015-01-07	Yeda Res & Dev	Hsp60, hsp60-peptide und t-zellen-impfstoffe zur immunmodulation
JP2008531730A (ja) *	2005-03-04	2008-08-14	キュアーディーエム、インク．	Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
US7393919B2 (en)	2005-05-25	2008-07-01	Cure Dm, Inc.	Peptides, derivatives and analogs thereof, and methods of using same
JP4283812B2 (ja) *	2006-01-06	2009-06-24	財団法人工業技術研究院	重症筋無力症の診断方法およびそのキット
WO2008064306A2 (en)	2006-11-22	2008-05-29	Curedm, Inc.	Methods and compositions relating to islet cell neogenesis
NZ599756A (en)	2007-08-30	2013-09-27	Curedm Group Holdings Llc	Compositions and methods of using proislet peptides and analogs thereof
CU23701A1 (es) *	2008-12-29	2011-09-21	Ct Ingenieria Genetica Biotech	Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
JP2015508812A (ja)	2012-03-01	2015-03-23	イエダリサーチアンドディベロプメントカンパニーリミテッド	非自己免疫性糖尿病を抑制および処置するためのｈｓｐ６０由来ペプチドおよびペプチド類似体
EP2819689A1 (de)	2012-03-01	2015-01-07	Yeda Research and Development Co. Ltd.	Regenerierung von beta-inselzellen durch hsp60-derivierte peptide
CN104418948B (zh) *	2013-09-10	2019-08-16	深圳翰宇药业股份有限公司	一种制备多肽药物的方法
CN104650209B (zh) *	2013-11-19	2018-04-06	深圳翰宇药业股份有限公司	多肽药物DiaPep277 的合成方法
CN104650244B (zh) *	2015-01-21	2017-12-08	中国药科大学	一种具有降血糖兼调脂作用的表位组合肽及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5114844A (en) *	1989-03-14	1992-05-19	Yeda Research And Development Co., Ltd.	Diagnosis and treatment of insulin dependent diabetes mellitus

1995
- 1995-12-20 DE DE69531004T patent/DE69531004T2/de not_active Expired - Lifetime
- 1995-12-20 NZ NZ301440A patent/NZ301440A/xx not_active IP Right Cessation
- 1995-12-20 MX MX9704738A patent/MX9704738A/es unknown
- 1995-12-20 PT PT95944502T patent/PT820303E/pt unknown
- 1995-12-20 RO RO97-01173A patent/RO116777B1/ro unknown
- 1995-12-20 SI SI9530664T patent/SI0820303T1/xx unknown
- 1995-12-20 UA UA97063404A patent/UA42040C2/uk unknown
- 1995-12-20 JP JP51996596A patent/JP3420245B2/ja not_active Expired - Fee Related
- 1995-12-20 HU HU9901771A patent/HU224160B1/hu active IP Right Grant
- 1995-12-20 EP EP95944502A patent/EP0820303B1/de not_active Expired - Lifetime
- 1995-12-20 DK DK95944502T patent/DK0820303T3/da active
- 1995-12-20 CN CNB95197680XA patent/CN1233417C/zh not_active Expired - Lifetime
- 1995-12-20 PL PL95321091A patent/PL184145B1/pl unknown
- 1995-12-20 ES ES95944502T patent/ES2201137T3/es not_active Expired - Lifetime
- 1995-12-20 AU AU46866/96A patent/AU707835B2/en not_active Expired
- 1995-12-20 AT AT95944502T patent/ATE242005T1/de active
- 1995-12-20 DE DE0820303T patent/DE820303T1/de active Pending
- 1995-12-20 BR BR9510102A patent/BR9510102A/pt active IP Right Grant
- 1995-12-20 WO PCT/US1995/016596 patent/WO1996019236A1/en active Search and Examination
- 1995-12-20 KR KR1019970704281A patent/KR100400480B1/ko not_active IP Right Cessation
- 1995-12-20 CZ CZ19971908A patent/CZ293784B6/cs not_active IP Right Cessation
- 1995-12-20 CA CA002208274A patent/CA2208274C/en not_active Expired - Lifetime
- 1995-12-21 HR HR950612A patent/HRP950612B1/xx not_active IP Right Cessation
- 1995-12-21 IL IL11649995A patent/IL116499A0/xx not_active IP Right Cessation
- 1995-12-21 RS YU78795A patent/RS49517B/sr unknown
- 1995-12-21 AR AR10071295A patent/AR002949A1/es unknown
- 1995-12-21 TR TR95/01630A patent/TR199501630A2/xx unknown
- 1995-12-21 UY UY24130A patent/UY24130A1/es unknown
1996
- 1996-01-05 TW TW085100088A patent/TW496872B/zh not_active IP Right Cessation
1997
- 1997-06-19 IS IS4510A patent/IS1966B/is unknown
- 1997-06-19 FI FI972669A patent/FI118373B/fi not_active IP Right Cessation
- 1997-06-19 NO NO19972849A patent/NO317350B1/no not_active IP Right Cessation
2003
- 2003-01-30 JP JP2003022033A patent/JP3554319B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
YU78795A (sh)	1998-05-15
EP0820303A4 (de)	1998-03-11
NO972849L (no)	1997-08-13
SI0820303T1 (en)	2003-10-31
HRP950612A2 (en)	1997-10-31
FI118373B (fi)	2007-10-31
DE820303T1 (de)	1999-05-20
EP0820303A1 (de)	1998-01-28
ES2201137T3 (es)	2004-03-16
RO116777B1 (ro)	2001-06-29
ATE242005T1 (de)	2003-06-15
CA2208274A1 (en)	1996-06-27
TW496872B (en)	2002-08-01
UA42040C2 (uk)	2001-10-15
JP2004026797A (ja)	2004-01-29
MX9704738A (es)	1997-10-31
PL184145B1 (pl)	2002-09-30
AR002949A1 (es)	1998-05-27
CN1233417C (zh)	2005-12-28
PL321091A1 (en)	1997-11-24
NO972849D0 (no)	1997-06-19
FI972669A0 (fi)	1997-06-19
AU4686696A (en)	1996-07-10
IL116499A0 (en)	1996-03-31
NZ301440A (en)	2000-01-28
CN1175214A (zh)	1998-03-04
DE69531004T2 (de)	2004-02-05
WO1996019236A1 (en)	1996-06-27
FI972669A (fi)	1997-08-15
PT820303E (pt)	2003-10-31
BR9510102A (pt)	1997-11-25
JPH10511649A (ja)	1998-11-10
IS4510A (is)	1997-06-19
TR199501630A2 (tr)	1996-07-21
DE69531004D1 (de)	2003-07-10
RS49517B (sr)	2006-10-27
DK0820303T3 (da)	2003-10-06
CZ293784B6 (cs)	2004-07-14
IS1966B (is)	2004-12-15
JP3420245B2 (ja)	2003-06-23
CZ190897A3 (en)	1997-11-12
UY24130A1 (es)	1996-06-11
JP3554319B2 (ja)	2004-08-18
EP0820303B1 (de)	2003-06-04
HRP950612B1 (en)	2003-12-31
HU224160B1 (hu)	2005-06-28
CA2208274C (en)	2005-12-06
KR100400480B1 (ko)	2003-12-31
AU707835B2 (en)	1999-07-22
HUT78092A (hu)	1999-09-28

Publication	Publication Date	Title
NO317350B1 (no)	2004-10-18	Peptid p277 analoger og farmasoytiske sammensetninger som omfatter disse for behandling eller diagnostikk av diabetes
JP3203323B2 (ja)	2001-08-27	インスリン依存性糖尿病の診断と治療
KR100454554B1 (ko)	2005-04-06	당뇨병 치료를 위한 인간의 열쇼크 단백질60 유래의 신규펩티드들, 조성물들, 방법들 및 키트들
KR101570383B1 (ko)	2015-11-19	조성물
US20060089302A1 (en)	2006-04-27	Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
US6180103B1 (en)	2001-01-30	Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
AU670024B2 (en)	1996-07-04	Methods of treating or preventing autoimmune uveoretinitis in mammals
US6309847B1 (en)	2001-10-30	Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases
RU2159250C2 (ru)	2000-11-20	АНАЛОГИ ПЕПТИДА p277 И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ И ДИАГНОСТИКИ ДИАБЕТА
JP2007119482A (ja)	2007-05-17	糖尿病の治療のためのヒト熱ショックタンパク質６０由来の新規ペプチド、組成物、方法およびキット
MXPA98000191A (en)	1998-10-23	Novedous peptides derived from human protein 60 produced by thermal shock, for the treatment of diabetes, compositions, methods and equi

Legal Events

Date	Code	Title	Description
2015-12-28	MK1K	Patent expired